Patient Population

The POLARIX trial demonstrates that POLIVY-R-CHP benefits a broad, representative population of 1L DLBCL patients1,2,3

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

Dr Hervé Tilly

University of Rouen, France

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

POLIVY-R-CHP benefits a broad 1L DLBCL patient population covering diverse age groups, geographic backgrounds, and clinical profiles1,3

SAFETY

Broad patient population

Broad patient population

 

POLIVY-R-CHP benefits a broad 1L DLBCL patient population covering diverse age groups, geographic backgrounds, and clinical profiles1,3

SAFETY

SAFETY

Real patient journeys demonstrating POLIVY’s
impact across diverse 1L DLBCL cases

Explore real-world cases to see how POLIVY transformed patients’ clinical outcomes

Similar efficacy was seen across patient subgroups4,5

Elderly patients ( ≥70 years)4

  • In patients aged >70–80 years, efficacy endpoints favoured POLIVY-R-CHP vs. R-CHOP, including progression-free survival as observed in the ITT population4
  • The analysis of this elderly population confirms the risk-benefit profile of POLIVY-R-CHP that was observed in the ITT population4

High-risk patients (young patients age ≤60 years, high-risk aaIPI 2,3)5,*

  • In a retrospective analysis, no significant differences in efficacy were seen in high-risk patients receiving POLIVY-R-CHP or R-CHOEP at 2 years5
  • Similar efficacy was seen across patient subgroups regardless of aaIPI 2 or 3 status at 2 years5

 

Elderly patients ( ≥70 years)4

  • In patients aged >70–80 years, efficacy endpoints favoured POLIVY-R-CHP vs. R-CHOP, including progression-free survival as observed in the ITT population4
  • The analysis of this elderly population confirms the risk-benefit profile of POLIVY-R-CHP that was observed in the ITT population4

High-risk patients (young patients age ≤60 years, high-risk aaIPI 2,3)5,*

  • In a retrospective analysis, no significant differences in efficacy were seen in high-risk patients receiving POLIVY-R-CHP or R-CHOEP at 2 years5
  • Similar efficacy was seen across patient subgroups regardless of aaIPI 2 or 3 status at 2 years5

 

*A retrospective analysis based on results from the POLIVY-R-CHP arm of POLARIX and the R-CHOEP arm of the Phase III Mega-CHOEP study5

“Our tumor board tries to get the best therapy for our patients. In certain situations, like those with stage III or IV DLBCL, we treat with POLIVY-R-CHP, and we have had great success with the therapy.”

– Dr Joachim Rettl

Hematologist and General Oncologist, Klinikum Klagenfurt am Wörthersee

Safety

How does the safety data for POLIVY-R-CHP compare to that of R-CHOP?

read more

1L=first line; aaIPI=age-adjusted International Prognostic Index; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + cyclophosphamide, doxorubicin, prednisone;
R-CHOEP, rituximab + cyclophosphamide, etoposide, doxorubicin, vincristine, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Sehn LH, Salles G. N Engl J Med. 2021;384:842-58.
  3. Salles G, et al. Oral presentation at: 66th ASH; December 2024; San Diego, USA.
  4. Hu B, et al. Poster presented at: 17th ICML; June 2023; Lugano, Switzerland.
  5. Lenz G, et al. Leukemia. 2024;38:2709-11.